IMMNOV — Immunovia AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK136.55m
- SEK80.94m
- SEK0.69m
Brief: Immunovia Further Strengthens IP Portfolio For Its IMMray Pancan-D Signature
Brief: Immunovia Q4 Net Loss SEK 47 Mln
Brief: Immunovia Appoints Philipp Mathieu As Acting CEO
Brief: Immunovia Appoints Philipp Mathieu As Acting CEO
Brief: Immunovia's CEO, Patrik Dahlen, To Step Down During 2022
Brief: Immunovia Q3 Pretax Loss Narrows To SEK 36.1 Mln
Brief: Immunovia Appoints Karin Almqvist Liwendahl As New CFO
Brief: Immunovia Enters Licensing Agreement With JW BioScience For Pancreatic Cancer Biomarkers
Brief: Immunovia Provides Updates On The Price For The IMMray PanCan-D Test In The US
Brief: Immunovia Gets Approval To Begin Testing Patients For Pancreatic Cancer With Immray Pancan-D Test
Brief: Immunovia Inc Receives Approval To Begin Testing Patients For Pancreatic Cancer With IMMray PanCan-d Test
Brief: Immunovia CEO Patrik Dahlen Buys 6,860 Shares In Co
Brief: Immunovia Q1 Pretax Loss Narrows To SEK 23.4 Million
Brief: Immunovia Presents Update On US Market Size For Immray PanCan-D In Familial/Hereditary Risk Group
Brief: Immunovia Posts Positive U.S. Clinical Validation Results Of Immray Pancan-D Blood Test
Brief: Immunovia Reports Improved Test Performance Of Immray Pancan-D
Brief: Immunovia Q4 Operating Loss Widens To SEK 38.1 Mln
Brief: Immunovia CEO Buys 15,000 Shares In Company
Brief: Immunovia Q3 Pre-Tax Loss Widens To SEK 38.1 Mln